Business
ANGLE launches Portrait+ CTC kit at SABCS
ANGLE launches Portrait+ CTC kit at SABCS.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n\n\n\nFor immediate release\n\n\n5 December 2023\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nANGLE LAUNCHES PORTRAIT+ CTC KIT AT San Antonio Breast Cancer Symposium\n \nANGLE's Portrait+ CTC staining kit combines the power of Parsortix® technology with an optimised immunofluorescent assay\n \n The test is designed for highly accurate, repeatable, and precise results allowing CTC identification, characterisation and enumeration\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce the launch of its Portrait®+ CTC staining kit at the San Antonio Breast Cancer Symposium (SABCS).\n \nThe Portrait+ CTC staining kit is a ready-to-use kit for the identification, characterisation and enumeration of epithelial and mesenchymal cancer cells including those undergoing epithelial-to-mesenchymal transition (EMT). EMT is a key transition step in cancer cells, and is associated with tumour progression, the development of drug resistance, and metastasis.\n \nThis launch follows extensive development, optimisation and validation of the kit to provide advanced immunofluorescent (IF) staining of CTCs harvested from a patient blood sample by the Parsortix technology. The performance of current CTC protocols being used by academic and research institutions varies considerably. ANGLE has developed its test for reliable repeatable results with a fully validated, standardised protocol to make it easy for customers to adopt. Key features of the product include:\n \n· use of a direct staining technique and an optimised, vivid dye combination to ensure high signal intensity while maintaining high analytical specificity and sensitivity\n \n· pre-mixed and freeze-dried antibodies for ease-of-use and l...